

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,541,435 B2  
APPLICATION NO. : 10/517726  
DATED : June 2, 2009  
INVENTOR(S) : Amanda Proudfoot and Marie Kosco-Vilbois

Page 1 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 2,

Line 30, "tubercolosis" should read --tuberculosis--.

Column 3,

Line 52, "established that is not possible" should read  
--established that it is not possible--.

Column 4,

Lines 13-14, "mutants having not only have a considerably" should read  
--mutants having not only a considerably--.

Column 5,

Line 4, "pico microMolar" should read --pico -/microMolar--.

Column 6,

Line 25, "to Alanine" should read --with Alanine--.  
Line 30, "substituted to" should read --substituted with--.  
Line 43, "substituted to" should read --substituted with--.  
Line 49, "substituted to" should read --substituted with--.  
Line 67, "substituted to" should read --substituted with--.

Column 7,

Lines 41-42, "of some of basic" should read --of some of the basic--.  
Lines 44-45, "of these group of chemokines" should read --of these chemokines--.

Column 8,

Line 66, "or im proving" should read --or improving--.

Column 9,

Line 17, "proteinsu" should read --proteins"--.

Column 10,

Line 34, "compounds of present invention" should read  
--compounds of the present invention--.

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,541,435 B2

Page 2 of 2

APPLICATION NO. : 10/517726

DATED : June 2, 2009

INVENTOR(S) : Amanda Proudfoot and Marie Kosco-Vilbois

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 12,

Line 8, "Many books and reviews provides" should read

--Many books and reviews provide--.

Line 40, "derived form viral" should read --derived from viral--.

Column 15,

Line 2, "to which is administered" should read --to which it is administered--.

Lines 60-61, "the desiredr results" should read --the desired results--.

Column 22,


Table III, "CXCLII-WT	should read --CXCL11-WT
CXCLII-1B3	CXCL11-1B3
CXCLII-2B3"	CXCL11-2B3--.

Column 23,

Table III, "CXCLII-3B3	should read --CXCL11-3B3
CXCLII-4B4"	CXCL11-4B4--.

Signed and Sealed this

First Day of September, 2009



David J. Kappos  
Director of the United States Patent and Trademark Office